Oxeglitazar

Oxeglitazar

SCHEMBL3605899

COc1ccc2c(c1)C(/C=C/C(C)=C\C(=O)O)=CC(C)(C)CO2

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 11/20 0.41
RARB P10826 6/20 0.41
RARG P13631 6/20 0.41
RARA P10276 4/20 0.41
RXRG P48443 7/20 0.36
RXRB P28702 6/20 0.36
MAPT P10636 5/20 0.35
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 3/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
CYP19A1 P11511 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
RAB9A P51151 2/20 0.34
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
HPGD P15428 1/20 0.34
ALOX12 P18054 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HTR7 P34969 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxeglitazar SCHEMBL1547427 1.00 RXRA (0.41) RXRARARBRARGRARARXRG
Oxeglitazar SCHEMBL29372761 1.00 RXRA (0.41) RXRARARBRARGRARARXRG
Oxeglitazar SCHEMBL1547425 1.00 RXRA (0.41) RXRARARBRARGRARARXRG
SCHEMBL13993030 0.93 MAPT (0.35) RXRARARBRARGRARAMAPT
SCHEMBL3600984 0.92 RXRA (0.39) RXRARARBRARGRARARXRG
SCHEMBL3600980 0.92 RXRA (0.39) RXRARARBRARGRARARXRG
SCHEMBL3609445 0.92 RXRA (0.39) RXRARARBRARGRARARXRG
SCHEMBL3609449 0.92 RXRA (0.39) RXRARARBRARGRARARXRG
SCHEMBL3604855 0.89 RXRA (0.40) RXRARARBRARGRARARXRG
SCHEMBL3604858 0.89 RXRA (0.40) RXRARARBRARGRARARXRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160410-A1 USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA BOIZEL ROBERT 2010-06-24 US claimed
US-20070099854-A1 Use of pentadienoic acid derivatives for the treatment of hyperuricemia MERCK PATENT GMBH (DE) 2007-05-03 US claimed
US-20100160410-A1 USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA BOIZEL ROBERT 2010-06-24 US disclosed
US-20070099854-A1 Use of pentadienoic acid derivatives for the treatment of hyperuricemia MERCK PATENT GMBH (DE) 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099854-A1 Use of pentadienoic acid derivatives for the treatment of hyperuricemia XDH, URB2, ALOX12 RXRA 61/4885RARB 354/4885RARG 405/4885
US-20100160410-A1 USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA XDH, URB2, ALOX12 RXRA 61/4885RARB 354/4885RARG 405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.